Based on its strong focus on the Asian market, French metabolic diseases biotech company Poxel has made another significant move to solidify its position, forming a fully-owned Japanese subsidiary, Poxel KK. 13 September 2018
Rheos Medicines, a Boston, USA, biotech developing novel medicines that modulate metabolic pathways in immune cells to treat disease, has poached an experienced big pharma R&D leader from Roche to be its new chief executive. 6 September 2018
Rare diseases specialist Swedish Orphan Biovitrum has appointed Anne Marie de Jonge Schuermans as head of its new Technical Operations organization, bringing together Sobi’s manufacturing operations/biological development and supply, quality, supply chain, procurement and environment and safety operations. 22 August 2018
UK biopharma firm PureTech Health has announced the appointment of Dr Steven Paul, as chief executive of its affiliate, Karuna Pharmaceuticals. 15 August 2018
Following the resignation of Dr Andrew Cheng, chief medical officer of US biotech major Gilead Sciences, the company has announced two promotions. 15 August 2018
Namir Hassan has been named chief scientific officer of Zelluna Immunotherapy, a privately-held Norwegian biotech specializing in T-cell receptor (TCR) immunotherapies. 13 August 2018
CAR-T therapy company Cellectis announced on Friday that Stefan Scherer, vice president and global lead for early development and innovation at Novartis, would join the company in a leadership role. 3 August 2018
Privately-owned UK biotech Cell Medica has named Chris Nowers its new chief executive after its founder and former leader Gregg Sando stepped down. 1 August 2018
In the 1980s, technologies such as DNA editing started to mature, creating a range of sophisticated and transformative therapeutic techniques - and a race to secure funding, technologies and expertise. 27 July 2018
Along with announcing analysts’ expectation-beating financials, leading biotech firm Amgen's outlined planned executive succession to address upcoming departures of two executive vice presidents. 27 July 2018
As was widely expected, US biotech Gilead Sciences late yesterday posted another quarter of falling sales and profits, but surprised with the announcement that both its chief executive and chairman were departing from the company. 26 July 2018
OncoSec Medical, a company developing intratumoral cancer immunotherapies, today announced the appointment of Sara Bonstein as Chief Financial Officer and Chief Operating Officer. 16 July 2018
USA-based biotech CytoDyn says it has signed a non-binding letter of intent regarding a proposed acquisition of intellectual property and other assets of ProstaGene. 16 July 2018
Chugai Pharma Europe, a wholly-owned subsidiary of Chugai Pharmaceutical and its majority owner Roche, has announced the hiring of Troy Robinson as managing director of its UK operations. 3 July 2018
Tilos Therapeutics, a biotech firm developing anti-LAP antibodies for the treatment of cancer, fibrosis and autoimmune diseases, today announced the appointment of Jessie English as chief scientific officer. 27 June 2018
China’s Zai Lab, a Shanghai-based innovative biopharmaceutical company, has appointed that William Liang as chief commercial officer, reporting to Dr Samantha Du, Zai Lab’s chief executive. 11 June 2018
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024